Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

ESMO open·2026
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2023
Same author

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Related Experiment Video

Updated: Mar 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Systemic therapy for recurrent meningioma.

E Le Rhun1,2,3, S Taillibert4,5, M C Chamberlain6

  • 1a Lille University, PRISM Inserm U1191 , Villeneuve d'Ascq , France.

Expert Review of Neurotherapeutics
|April 29, 2016
PubMed
Summary

Systemic therapies for recurrent meningioma show limited efficacy. Vascular endothelial growth factor inhibitors suggest potential activity, but require further validation in randomized trials for brain tumor treatment.

Keywords:
Meningiomabevacizumabhydroyxureasunitinibsystemic therapytrabectedinvalitinib

More Related Videos

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

4.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Mar 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

4.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Brain tumor research

Background:

  • Meningioma accounts for 20-30% of primary brain tumors.
  • Recurrent meningioma poses a challenge after surgery and radiotherapy.
  • Evidence for systemic therapy in recurrent meningioma is limited.

Purpose of the Study:

  • To summarize current systemic therapies for recurrent meningioma.
  • To identify potential novel therapeutic targets and prognostic markers.

Main Methods:

  • Review of existing literature on systemic therapies for recurrent meningioma.
  • Expert commentary on the efficacy of various agents.
  • Discussion of emerging therapeutic strategies and biomarkers.

Main Results:

  • Many systemic agents (e.g., hydroxyurea, temozolomide) demonstrate limited efficacy.
  • Vascular endothelial growth factor (VEGF) inhibitors show potential but need validation.
  • TERT promoter, KLF4, AKT1, TRAF7, and SMO mutations are potential new targets.

Conclusions:

  • Current systemic options for recurrent meningioma are largely ineffective.
  • VEGF inhibitors represent a promising avenue requiring further clinical trials.
  • Biomarker discovery is crucial for advancing recurrent meningioma treatment.